What Vigadol Treats: Main Uses and Benefits

The primary therapeutic utility of Vigadol, which contains Sildenafil, is associated with symptomatic relief across key domains. The medication is used across two distinct symptom domains where additional symptomatic support is appropriate.

---

Easing Vascular-Driven Erection Difficulties

Vigadol provides targeted therapeutic support for erectile impairment, a condition where patients struggle to attain or sustain penile rigidity adequate for satisfactory sexual function. The primary benefit is that it provides supportive relief when symptoms interfere with daily comfort, generally allowing adult males to cope more steadily with recurrent functional challenges and helps ease the emotional burden associated with the inability to perform sexual activities.

Quick Fact: Relief for Functional Strain Vigadol is often used when symptoms of erectile difficulty interfere with daily functioning and require supportive management to assist with maintaining functional stability.

---

Supportive Management of Pulmonary Arterial Hypertension (PAH)

This medication is also used in the chronic management of Pulmonary Arterial Hypertension, a condition marked by increased physiological stress due to high pressure in the lung arteries. It helps ease symptoms such as debilitating shortness of breath, fatigue, and dizziness associated with these manifestations. The therapeutic benefit is that it is applied in addressing symptoms that interfere with daily functioning and contributes to easing the overall symptom load, which supports patients during difficult episodes by easing distress and supports general well-being during symptomatic phases.

Regulatory References

1. NIH MedlinePlus Drug Information

Official Eligibility and Contraindications

Vigadol (sildenafil) is not safe or effective for everyone. Governmental regulatory documents define strict rules for its use, based on the risk of severe side effects or a lack of established safety.

Do NOT use Vigadol if you have:

• Hypersensitivity or allergy to sildenafil or any component in the product.
• Concomitant use of organic nitrates in any form (e.g., nitroglycerin), as this combination can cause a severe, life-threatening drop in blood pressure.
• Concomitant use of riociguat (a guanylate cyclase stimulator), which also carries a risk of severe hypotension.

Use is Not Recommended or Requires Special Consideration in:

Group/Condition	Eligibility Status
Pediatric patients (PAH)	Not recommended, especially for chronic use, due to concerns over increased mortality observed in clinical trials.
Severe Hepatic Impairment	Not studied and therefore not recommended.
Pulmonary Veno-Occlusive Disease (PVOD)	Not recommended, as administration may cause serious pulmonary edema.
Retinitis Pigmentosa	Use is not recommended due to a lack of controlled clinical data.
Resting Hypotension	Use with caution, as patients may be adversely affected by the drug's vasodilatory effects.
Pregnancy/Lactation	No adequate studies in pregnant women. Not recommended for use in nursing mothers.

Vigadol (calcitriol, an active form of vitamin D) can interact with several other medications, which may affect its effectiveness or increase the risk of side effects, particularly hypercalcemia (high calcium levels in the blood).

It is essential to inform your healthcare provider about all prescription and non-prescription drugs, supplements, and herbal products you are taking.

Medications that Increase Hypercalcemia Risk

Combining Vigadol with certain drugs can significantly elevate the risk of dangerously high calcium levels. These include:

• Other Vitamin D analogues or supplements: Taking additional vitamin D or its derivatives (e.g., calcifediol) should be strictly avoided.
• Thiazide Diuretics: Medicines like hydrochlorothiazide or bendroflumethiazide, often used for high blood pressure or fluid retention, reduce calcium excretion, increasing the risk of hypercalcemia when used with Vigadol.
• High-Dose Calcium-Containing Products: Excessive intake of calcium supplements or calcium-containing antacids should be monitored carefully.

Medications that Affect Vigadol’s Absorption or Metabolism

• Corticosteroids: These medicines, such as prednisone, may oppose the effects of Vigadol by decreasing calcium absorption.
• Bile Acid Sequestrants: Drugs like cholestyramine, used to lower cholesterol, can reduce the absorption of Vigadol from the gut.
• Certain Anticonvulsants: Some seizure medications, like phenytoin or phenobarbital, may speed up the breakdown of Vigadol, reducing its effectiveness.

Other Significant Interactions

Vigadol may also affect the action of other drugs. For instance, the toxicity of cardiac glycosides (e.g., digoxin) can be increased if Vigadol causes hypercalcemia, potentially leading to serious heart rhythm problems. Additionally, phosphate-binding agents may interact, requiring careful dose adjustment to prevent abnormal phosphate levels.

How Vigadol Works: Mechanism of Action

Vigadol influences an enzyme-driven pathway by targeting a specific enzyme, resulting in changes to smooth muscle tone and local hemodynamics in certain vascular beds. The drug acts as a selective competitive inhibitor of the Phosphodiesterase type 5 (PDE5) enzyme, which catalyzes the hydrolysis of cyclic Guanosine Monophosphate (cGMP).

Inhibition of PDE5 results in an increased steady-state concentration of cGMP within the smooth muscle cells of certain vascular walls. This resultant increase in cGMP concentration facilitates the relaxation of smooth muscles within the walls of specific arteries (e.g., in the corpus cavernosum and pulmonary arteries), leading to vasodilation. This smooth muscle relaxation changes local vascular resistance, which is expressed as vasodilation and a subsequent change in local hemodynamics. This effect requires the upstream release of the signaling molecule Nitric Oxide.

Official Administration and Dosage Instructions

Vigadol (Sildenafil) is administered differently based on the condition being addressed. The approved routes of administration are Oral (tablets or suspension) and Intravenous (IV) injection, which is typically reserved for patients with Pulmonary Arterial Hypertension (PAH) temporarily unable to take the oral form.

---

Dosing for Erectile Difficulty (ED)

Parameter	Oral Dosage (Tablet)
Standard Starting Dose	50 mg
Maximum Single Dose	100 mg
Frequency	As needed, maximum once per day
Timing	Approximately 1 hour before activity, or anytime from 30 minutes to 4 hours prior

When taken for ED, tablets can be consumed with or without food, though a high-fat meal may delay the onset of activity. A starting dose of 25 mg should be considered for patients 65 years old, those with severe renal or hepatic impairment, or those taking certain CYP3A4 inhibitors.

---

Dosing for Pulmonary Arterial Hypertension (PAH)

Parameter	Recommended Dose and Route
Oral Dose (Adults)	20 mg three times a day (TID)
IV Dose (Adults)	10 mg TID (equivalent to 20 mg oral)
Dosing Schedule	Doses should be taken approximately 4 to 6 hours apart

The oral suspension must be shaken well (e.g., for at least 10 seconds) before each use. Pediatric patients are given weight-based oral doses, for example, 10 mg TID for those ≤ 20 kg.

Research Evidence / Overview of Studies for Vigadol

The following information describes the types of research that research examined for Vigadol in relation to its main areas of focus. These findings describe group patterns and contribute to the broader evidence landscape but do not provide individual predictions or clinical recommendations.

---

Evidence for use in Low Back Pain

Research examined Vigadol in populations with low back pain, a condition characterized by functional limitations. The available evidence primarily comes from short-term trials, often lasting a few weeks to a couple of months. Researchers monitored outcomes related to physical discomfort and daily functioning. Studies conducted during these defined time intervals data show patterns related to how physical discomfort and function evolved in the observed populations receiving the intervention compared to control groups. However, the results apply only to the populations studied and the brief follow-up durations were limited.

---

Evidence for use in Osteoarthritis

Vigadol research explored in populations with osteoarthritis, a condition marked by functional limitations and joint discomfort. The studies often involved randomized controlled trials (RCTs), which are considered a structured approach to evidence, though many were short-term. The research examined outcomes related to physical discomfort and outcomes reflecting daily functioning. Studies report how symptoms evolved in the observed populations over the study duration. However, the available evidence is limited to measurements over a defined time interval, and the evidence quality varies across studies due to differences in design and formulation.

---

What is Still Uncertain About Vigadol

The evidence landscape, while providing some context, highlights several areas of uncertainty where research is ongoing and more is needed. Long-term outcomes are not fully established across the indications research examined for Vigadol, as the follow-up durations were limited in most key trials. Data for certain groups remain insufficient, particularly for children or pregnant individuals. The findings were mixed across some studies, underscoring that the consistency of observed patterns needs further exploration.

Common questions about Vigadol (FAQ)

Q: What should I do if my erection lasts longer than 4 hours after taking the medicine?

Priapism, which is a prolonged or painful erection lasting more than 4 hours, is a serious, rare adverse reaction documented in the official labeling for sildenafil. The official patient information states that immediate medical attention is required for this condition. This serious adverse reaction requires professional evaluation.

Q: What foods or drinks should I avoid when taking Vigadol for ED?

Regulatory product information indicates that sildenafil can be taken with or without food. However, taking the dose alongside a high-fat meal may lead to a delay in how quickly the medicine begins to work. Patients are advised to consult with their healthcare provider regarding their specific diet.

Q: Can women take Vigadol for any medical condition?

Official regulatory documents indicate that the active ingredient in Vigadol (sildenafil) is approved for use in both men and women for the treatment of Pulmonary Arterial Hypertension (PAH). For the treatment of Erectile Difficulty (ED), the product information is specific to adult males.

Q: How long does the effect of a single dose of Vigadol typically last?

According to official regulatory and scientific documents, the drug's plasma half-life—the time it takes for half of the drug to be eliminated from the body—is approximately 4 hours. This measure provides an indication of how long the active drug remains present in the body to produce its effects.

Q: Is it safe to drink alcohol when taking Vigadol?

Official product information suggests that consuming large amounts of alcohol while taking sildenafil may increase the potential for the drug’s vasodilatory (blood pressure-lowering) effects, which could increase the risk of symptoms like dizziness. Patients should consider limiting alcohol intake, and are advised to discuss their alcohol consumption with their healthcare provider.

Q: What happens if I accidentally take two doses of Vigadol for ED at the same time?

Official regulatory documents address the possibility of taking doses higher than the maximum recommended limit. In these instances, studies report that adverse events were similar in nature to those seen at lower, recommended doses but occurred more frequently. Patients who believe they have taken more than the recommended dose are advised to contact a healthcare professional or Poison Control Center for guidance.

Q: If I miss a dose of Vigadol for PAH, what should I do?

Official patient instructions for sildenafil used in Pulmonary Arterial Hypertension (PAH) generally advise that if a dose is missed, patients should take the next dose as soon as they remember, provided it is not almost time for the next scheduled dose. Regulatory documents explicitly state not to double the dose to compensate for a missed one.

Q: Does Vigadol start working immediately after I take it?

Regulatory information advises taking the medication for Erectile Difficulty approximately one hour before anticipated activity. However, the product label indicates it can be effective when taken anywhere from 30 minutes to 4 hours prior. This window shows the range during which the onset of action typically occurs.

Official Storage and Disposal Requirements

Storing Vigadol strictly according to official regulatory guidelines ensures product quality and prevents accidental harm. All medication must be kept out of the sight and reach of children and pets at all times.

Storage Component	Official Requirement
Temperature & Environment	Store in the original, labeled container in a cool, dry place. Avoid excessive heat, freezing, and moisture.
Stability	Do not use the medicine after the expiration date printed on the container label. Follow any specific "use-by" times for reconstituted solutions.
Handling	Ensure safety caps are locked. Do not use if the product is discolored or contains foreign particles.

Disposal must follow regulated pathways. The preferred method for unused or expired Vigadol is an official drug take-back program. If this is unavailable, mix the medicine with an undesirable substance, seal it in a container, and place it in the household trash. Do not flush down the toilet unless the medicine is specifically listed by a regulatory body for flushing.